.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC52_FluorouracilCombinations.FluorouracilCombinations .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC52_FluorouracilCombinations.FluorouracilCombinations| name: | FluorouracilCombinations | |
| ATC code: | L01BC52 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 500 | mg |
| volume of distribution: | 12.7 | L |
| clearance: | 1320 | mL/min |
| other parameters in model implementation | ||
Fluorouracil (5-FU) is a pyrimidine analog and antimetabolite that interferes with DNA synthesis. It is commonly used as a chemotherapeutic agent for various solid tumors, including colorectal, breast, head and neck, and gastrointestinal cancers. In combinations, 5-FU is used with other cytostatic drugs to enhance therapeutic efficacy. Fluorouracil remains a standard treatment modality and is approved for use in multi-agent chemotherapy protocols.
Population pharmacokinetics of fluorouracil in adult cancer patients, both sexes, with various solid tumors, receiving fluorouracil in combination protocols as part of standard intravenous chemotherapy regimens.